EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma

Jitong Zhou iD, Meng Gao, Shikun Zhang, Wing-Wa Guo, Wenzhi He, Minghe Zhang, Xi Chen, Cairang Dongzhi, Xiaomian Li, Yufeng Yuan, Weijie Ma iD

Advanced Science · 2025-07 · 12 (27)

DOI: 10.1002/advs.202501730 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, online erschienen am 08.05.2025. Verfasst von Jitong Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Ferroptosis, Liver Neoplasms, Phenylurea Compounds. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Wuhan, National Natural Science Foundation of China, Medical Sci-Tech innovation platform of Zhongnan Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advanced hepatocellular carcinoma (HCC) is characterized by poor prognosis, primarily due to limited therapeutic options and resistance to treatment. Although the combination of tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) has shown promising potential, the underlying mechanisms remain inadequately understood. Here, serine/threonine‐specific protein phosphatase (PP1A) is upregulated in Lenvatinib‐resistant HCC cells and correlates with poor prognosis. Functional experiments revealed that PP1A promotes HCC progression both in vitro and in vivo. Transcriptomic analysis and ferroptosis metabolite profiling (e.g., ROS, Fe 2 ⁺, lipid‐ROS, and GSH) demonstrated that PP1A inhibits Lenvatinib‐induced ferroptosis by dephosphorylating Keap1 at site 104. This disruption of the Keap1‐Nrf2 interaction enhances the transcription of ferroptosis‐related markers and immune checkpoint PD‐L1. Notably, single‐cell sequencing and co‐culture experiments revealed that PP1A knockdown alleviates T cell exhaustion and immune evasion, thereby improving antitumor immunity. In vivo experiments further demonstrated that PP1A knockdown significantly enhances the efficacy of Lenvatinib‐ICIs combination therapy. Overall, our findings highlight PP1A as a critical regulator of ferroptosis and antitumor immunity, suggesting its potential as a predictive biomarker and therapeutic target for improving outcomes in advanced HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularFerroptosisLiver NeoplasmsPhenylurea CompoundsQuinolinesProtein Phosphatase 1Immune Checkpoint InhibitorsHumansMiceAnimalsCell Line, TumorMaleFemaleMice, Nude

Stichwörter der Autor:innen

PD‐L1PP1Acombination therapyferroptosisimmune checkpoint inhibitorslenvatinib

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesProtein Phosphatase 1Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Hepatobiliary and Pancreatic Surgery, Zhongnan Hospital of Wuhan University, Wuhan, 430071, P. R. China.
  • Clinical Medicine Research Center for Minimally Invasive Procedure of Hepatobiliary & Pancreatic Diseases of Hubei Province, Wuhan, 430071, P. R. China.
  • TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan, 430071, P. R. China.

ORCID-Profile: Jitong Zhou, Weijie Ma

Förderung

  • Natural Science Foundation of Wuhan
  • National Natural Science Foundation of China
  • Medical Sci-Tech innovation platform of Zhongnan Hospital

Zitieren

APA

Zhou, J., Gao, M., Zhang, S., Guo, W. W., He, W., Zhang, M., Chen, X., Dongzhi, C., Li, X., Yuan, Y., & Ma, W. (2025). PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma. Advanced Science, 12(27). https://doi.org/10.1002/advs.202501730

Vancouver

Zhou J, Gao M, Zhang S, Guo WW, He W, Zhang M, et al. PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma. Advanced Science. 2025;12(27). doi:10.1002/advs.202501730

BibTeX
@article{Zhou2025,
  author = {Zhou, Jitong and Gao, Meng and Zhang, Shikun and Guo, Wing-Wa and He, Wenzhi and Zhang, Minghe and Chen, Xi and Dongzhi, Cairang and Li, Xiaomian and Yuan, Yufeng and Ma, Weijie},
  title = {PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma},
  journal = {Advanced Science},
  year = {2025},
  volume = {12},
  number = {27},
  doi = {10.1002/advs.202501730}
}
Kostenlos starten →